4-Jun-2026
Bank of America Securities Sticks to Its Buy Rating for Resmed (RMD)
TipRanks (Thu, 4-Jun 6:57 AM ET)
TipRanks (Wed, 3-Jun 11:06 PM ET)
Globe Newswire (Wed, 3-Jun 7:40 AM ET)
TipRanks (Wed, 3-Jun 7:30 AM ET)
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Globe Newswire (Mon, 1-Jun 4:05 PM ET)
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
Globe Newswire (Tue, 19-May 4:05 PM ET)
Resmed and OURA Partner to Expand Access to Sleep Health Education and Care
Globe Newswire (Tue, 19-May 9:00 AM ET)
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
Globe Newswire (Thu, 30-Apr 4:10 PM ET)
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Globe Newswire (Thu, 30-Apr 4:05 PM ET)
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
Globe Newswire (Wed, 1-Apr 4:05 PM ET)
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
Resmed trades on the NYSE stock market under the symbol RMD.
As of June 4, 2026, RMD stock price climbed to $194.32 with 1,474,158 million shares trading.
RMD has a beta of 0.49, meaning it tends to be less sensitive to market movements. RMD has a correlation of 0.06 to the broad based SPY ETF.
RMD has a market cap of $28.31 billion. This is considered a Large Cap stock.
Last quarter Resmed reported $1 billion in Revenue and $2.86 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.06.
In the last 3 years, RMD traded as high as $293.81 and as low as $132.24.
The top ETF exchange traded funds that RMD belongs to (by Net Assets): VTI, VOO, VO, VUG, IVV.
RMD has underperformed the market in the last year with a price return of -20.4% while the SPY ETF gained +28.2%. RMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.5% and -7.4%, respectively, while the SPY returned +11.5% and +2.1%, respectively.
RMD support price is $183.05 and resistance is $189.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RMD shares will trade within this expected range on the day.